Product Pipeline

 
HP163
  • In-vivo studies show evidence of single agent efficacy and anti-tumor immune activation
  • The IND enabling pre-clinical development program of HP163 is ongoing
 
After extensive drug discovery and lead optimization efforts, Hercules’ scientists have identified HP163 that blocks the AhR receptor and has suitable pharmaceutical properties to be developed as a drug.